The Antibiotic Pipeline Is Failing for Economic Reasons, Not Scientific Ones

The standard account of antimicrobial resistance describes a scientific failure: bacteria evolve, discovery is hard, the pipeline is empty. The first two claims are true and the third is misleading. Novel antibiotics have been discovered, developed, and approved over the past decade. Several of the companies that brought them to market then went bankrupt, sometimes within two years of approval.

That is not a discovery problem. It is a revenue model that is structurally incompatible with responsible use of the product.

The conservation paradox

For most pharmaceuticals, a superior product should be prescribed widely. For a novel antibiotic effective against resistant organisms, the correct clinical and public health behaviour is the opposite: hold it in reserve, use it only when older agents fail, and thereby preserve its effectiveness for as long as possible.

Stewardship programmes exist specifically to enforce that restraint, and they work. They also mean that a successful new antibiotic, judged by public health value, generates minimal sales volume.

• Revenue scales with use, and appropriate use is deliberately minimised.
• Treatment courses are short. A week or two of therapy, compared with years of a chronic medication.
• Price resistance is severe. Antibiotics are benchmarked against generics costing very little, so premium pricing meets institutional resistance regardless of novelty.
• Patent life burns during reserve. Exclusivity runs while the drug is deliberately unused, so peak sales arrive after generic entry becomes possible.

We built the thing the guidelines asked for, and the guidelines then correctly instructed hospitals not to use it. There was no version of this where we made money.

What happened to the companies

The pattern has repeated enough to be predictive. A small company takes a novel agent through clinical development, secures approval on the strength of activity against resistant organisms, and then discovers that hospital formularies are slow to add it, stewardship committees restrict it appropriately, and annual revenue lands one or two orders of magnitude below what was needed to service development debt.

The company is sold at a loss or files for bankruptcy. The asset transfers to a larger firm that keeps it on the shelf, or in some cases withdraws it. The clinical need it addressed remains unmet in practice even though a licensed product exists.

Large pharmaceutical companies drew the obvious conclusion years ago and mostly exited antibacterial discovery. The remaining pipeline sits with small firms and academic groups that will face the same economics on approval.

The proposed fixes, and their track records

Two categories of intervention have been tried. Push incentives subsidise development: grants, non-dilutive funding, and public-private partnerships for early research. These have worked reasonably well at their stated purpose, which is why there are candidates at all.

Pull incentives are supposed to reward approval, and they are where the model still fails. Extended exclusivity does little when the constraint is volume rather than competition. Priority review vouchers are tradeable and have produced real value, but they are a one-off payment poorly matched to the size of the gap.

The mechanism with the strongest logic decouples payment from volume entirely. Under a subscription or availability model, a health system pays a fixed annual sum for guaranteed access to an antibiotic regardless of how much is dispensed. The developer receives predictable revenue; the health system retains every incentive to restrict use.

Pilot programmes in a small number of national health systems have demonstrated that this is administratively workable. The limitation is scale. A subscription from one or two countries does not underwrite global development costs, and the coordination problem across payers has not been solved.

What to watch

Two indicators matter more than pipeline counts. The first is whether subscription-style procurement expands beyond pilots to a group of payers large enough to constitute a viable market. The second is whether any newly approved agent reaches profitability under current arrangements, which so far none has.

Until one of those changes, additional research funding will continue producing approved drugs that bankrupt their developers. For the parallel problem of evidence that never reaches the public record, see our reporting on unreported clinical trials.